Brett Haumann, MBBCh, MBA joins RIGImmune with 30 years’ industry experience and expertise including senior leadership roles in large pharma and biotech companies in the US and UK. Dr. Haumann has served as chief medical officer in both private and publicly listed companies, including Circassia, Theravance Biopharma (where he oversaw the approval of inhaled Yupelri^® for COPD) and ReViral (acquired by Pfizer in 2023). Previously Dr. Haumann spent 15 years at GlaxoSmithKline in a variety of executive roles in South Africa and the UK, spanning early drug discovery to clinical development and commercialization, rising to Vice President and Medicines Development Leader at GSK and leading the development of inhaled products for the treatment of asthma and COPD, including Relvar^®, Breo^® and Arnuity^®.

Dr. Haumann also brings extensive life sciences venture investment experience from his ongoing role as an Operating Partner at SV Health Investors. Haumann has served as a non-executive director on the boards of several biopharmaceutical companies in the UK and US, including Autifony, Reacta and Aimmune (acquired by Nestle in 2020). Dr. Haumann currently serves a director for Aravax. He received his medical degree (MBBCh) from the University of Witwatersrand, South Africa, and his master’s in business administration (MBA) with distinction from the Open University, UK.